NeuroRx Submits Request for Emergency Use Authorization for RLF-100 ™ (aviptadil) in the Treatment of Patients with Critical COVID-19 and Respiratory Failure Who Have Exhausted Approved Therapy

RADNOR, Pa., Sept. 23, 2020 /PRNewswire/— NeuroRx, Inc. has submitted a request for an Emergency Use Authorization (EUA) with the US FDA for the use of RLF-100™ aviptadil in patients who are receiving intensive care and who have...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials